TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Healthy adults aged 18 to 50 years~* Resident in or near Oxford for the duration of the vaccination study~* Willingness to allow the investigators to discuss the volunteer's medical history with the volunteer's GP~* Screening Elispot positive (more than 50 spots/million PBMC) for at least any 1 of the 3 ESAT6 peptide pools or any one of the 3 CFP10 pools ; and screening Elispot positive for PPD.~* Heaf test grade II-IV or positive Mantoux test.~* CXR normal; or abnormal but not clinically significant CXR findings with no evidence of past/present TB infection or disease on the CXR.~* For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day of vaccination~* Agreement to refrain from blood donation during the course of the study~* Written informed consent~* Willingness to undergo an HIV~Exclusion Criteria~* Any deviation from the normal range in biochemistry or haematology blood tests or in urine analysis~* Heaf grade IV~* Prior receipt of a recombinant MVA or Fowlpox vaccine~* Use of any investigational or non-registered drug, live vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period~* Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune modifying drugs within six months of vaccination. (For corticosteroids, this will mean prednisolone, or equivalent, ε 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products~* Evidence of cardiovascular disease~* History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)~* History of insulin requiring diabetes mellitus~* Chronic or active neurological disease requiring ongoing specialist supervision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants from birth up to \<18 years of age and weighing ≥ 5 kilograms at the time of consent.~2. PNH diagnosis confirmed by documented high-sensitivity flow cytometry.~3. Presence of 1 or more of the following PNH-related signs or symptoms within 3 months of Screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia, history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of packed red blood cell transfusion due to PNH.~4. Lactate dehydrogenase (LDH) level ≥ 1.5 × upper limit of normal (ULN) for participants not being treated with eculizumab at screening and LDH level ≤ 1.5 × ULN for participants taking eculizumab.~5. Documented meningococcal vaccination not more than 3 years prior to dosing, and vaccination against Streptococcus pneumoniae and Haemophilus influenzae.~6. Female participants of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab.~Exclusion Criteria:~1. History of bone marrow transplantation.~2. History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation.~3. Unstable medical conditions (for example, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH).~4. Females who are pregnant or breastfeeding or who have a positive pregnancy test at screening or Day 1.~5. Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ravulizumab (Type: EXPERIMENTAL): Complement inhibitor treatment-naïve and eculizumab-experienced participants received ravulizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting to the UCSF oral medicine clinic diagnosed with either the atrophic or the erosive form of oral lichen planus~* Study subjects must have a symptom score between 3 to 8 at the time of entry into the study. (Range of scale: zero to ten with zero being no symptoms and ten being the worst imaginable symptoms.~* Study subjects will have discontinued systemic and/or topical steroids and/or curcuminoids for at least 2 weeks before entry into the study.~Exclusion Criteria:~* Pregnancy, lactation or unwillingness to use an effective method of contraception. An attempt will be made to ascertain the date of the last menstrual period among eligible pre-menopausal women. If pregnancy cannot be ruled out, a pregnancy test will be provided to the women before enrollment into the study. - Patients younger than 21 years of age.~* Patients who cannot return for a follow-up visit at two weeks after enrollment.~* Patients who have a medical contraindication to discontinuation of systemic steroids eg. those on long term corticosteroid therapy. - Patients with a history of gastro-esophageal reflux disease, gastric / duodenal ulcers, or gallstones.~* Patients with elevated liver enzymes;~* Patients on anticoagulants or antiplatelet medications.~* Patients undergoing orthodontic treatment.~* Patients who don't read, speak or understand English.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Curcumin (Type: EXPERIMENTAL): Curcumin C3 Complex
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Normal, healthy males and females 16 to 40 years of age~* Outpatients who have moderate to severe post-operative pain (confirmed by a Visual Analog Scale-Pain Severity Rating \[VAS-PSR\] score of at least 50 mm on a 100 mm VAS-PSR) following surgical extraction of two or more third molars, at least one of which must be a partial or complete bony mandibular impaction~* Use of only the following pre-operative medication(s)/anesthetic(s): topical benzocaine, a short acting parenteral (local) anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor and/or nitrous oxide~Exclusion Criteria:~* Pregnancy or breast-feeding~* Alcohol or substance abuse~* Any serious medical or psychiatric disorder~* History of stomach ulcers, stomach bleed, or other bleeding disorders~* Use of a prescription or over-the-counter drug with which administration of ibuprofen or any other non-steroidal anti-inflammatory drug, acetaminophen, or hydrocodone is contraindicated (including: opioids, antipsychotics, antianxiety agents, or other central nervous system depressants\[including alcohol\])

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment B (Type: ACTIVE_COMPARATOR): None
- Treatment C (Type: ACTIVE_COMPARATOR): None
- Treatment D (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject participated in study C87085 \[NCT00552058\] in which the subject completed the study at Week 6~* Subject is capable of providing informed consent, which must be obtained prior to any study related procedures~* Have a chest X-ray taken at Visit 1 that is read by a qualified radiologist or pulmonary physician, with no evidence of current active Tuberculosis (TB) or old inactive TB~* Subject has taken a TB survey and is committed to comply with TB prophylaxis if applicable~Exclusion Criteria:~* Subject is experiencing an ongoing serious adverse event assessed as being related to study medication or is experiencing a serious adverse event that is still not assessable~* Subject has an intercurrent illness that requires termination of treatment, such as a serious infection (e.g. TB, pneumonia, sepsis, pyelonephritis, fistula abscess)~* Subject is non-compliant with TB prophylactic treatment (if applicable)~* Subject has had a chest X-ray at Visit 1 that shows an abnormality suggestive of a malignancy or active infection, including TB~* Female who is pregnant or breast feeding~* Female of child bearing age or post puberty males not practicing effective birth control~* Subject is expecting to receive any live virus or bacterial vaccination within 3 months of first Study Medication administration, during the trial or 3 months after last dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Certolizumab Pegol (Type: EXPERIMENTAL): Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 0-21 years of age with a diagnosis of a immunodeficiency, congenital marrow failure syndrome, inborn error of metabolism, or hereditary anemia~* Appropriately matched related or unrelated umbilical cord blood unit with a cell dose ≥ 3 x 10e7cells/kg~* Performance score (lansky or karnofsky) greater than or equal to 70~* Adequate organ function (Creatinine ≤ 2.0 mg/dl and creatinine clearance ≥ 50 ml/min/1.73 m2; Hepatic transaminases (ALT/AST) ≤ 4 x normal; Shortening fraction \>26% or ejection fraction \>40% or \> 80% of normal value for age; Pulmonary function tests demonstrating CVC or FEV1/FVC of \>60% of predicted for age.)~* Informed consent~* Not pregnant or breast feeding~* Minimum life expectancy of at least 6 months~* HIV negative~* No uncontrolled infections at the time of cytoreduction~* Disease specific inclusion criteria~Exclusion Criteria:~* Patients with hemoglobinopathies \> 3 years of age~* UCB unit with a total nucleated cell count \< 3 x 10e7/kg or \> 2 antigen mismatching~* Available HLA-matched related living donor able to donate without previous UCB donation~* Allogeneic hematopoietic stem cell transplant within the previous 6 months~* Any active malignancy, MDS, or any history of malignancy~* Severe acquired aplastic anemia~* DLCO \< 60% of normal value for age; requirement for supplemental oxygen~* Uncontrolled bacterial, viral or fungal infection (currently taking medication and progression of clinical symptoms)~* Pregnancy or nursing mother~* HIV/HTLV seropositive, Hep B surface antigen positive, or HCV RNA positive by PCR~* Any condition that precludes serial follow-up

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- RIC Cord Blood Transplant (Type: EXPERIMENTAL): Reduced Intensity Conditioning for Umbilical Cord Blood Transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AISTCM-Outcome Measurement of Acute Ischemic Stroke With Traditional Chinese Medicine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischemic stroke diagnosis by CT/MRI scan~* Yin pattern of Traditional Chinese Medicine Theory~* 40-85 years old~* Total anterior circulation infarcts (TACI), partial anterior territory cerebral infarction (PACI), lacunar anterior circulation infarcts (LACI) type under Oxfordshire Community Stroke Project (OCSP) standard~* NIHSS \>=4;~* Glasgow coma scale (GCS) \>=7;~* Modified Rankin Scale less than 2 degrees before onset of this stroke~* Informed consent signed by patient or his/her family~Exclusion Criteria:~* Hemorrhagic stroke;~* Coma, GCS\<=7;~* Cerebral hernia;~* Serious heart, liver, lung, kidney functional failure;~* Gastrointestinal (GI) bleeding;~* Thrombolysis drugs or surgery was administrated to the patient;~* Not cooperative with physician;~* Psychological disorder;~* Already taken part in other clinical drug trial within the past 3 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Chinese herbal medicine (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~- Documented S. aureus bacteremia~Exclusion Criteria~- Patients who had received or would have received more than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization. The following agents were considered potentially effective antistaphylococcal therapy: antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin), cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and linezolid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telavancin (Type: EXPERIMENTAL): None
- Vancomycin, nafcillin, oxacillin, or cloxacillin (Type: ACTIVE_COMPARATOR): Vancomycin 1 Gram/12 hours or nafcillin, oxacillin, or cloxacillin 2 Gram/6 hours (IV) intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of New Intermittent Catheters in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum 18 years of age and with full legal capacity~* Written informed consent and signed letter of authority and secrecy agreement given~* Willing to comply with not using analgesics 1 up to 24 hours prior to catheterization visits~* Urine Multistix negative for erythrocytes (hematuria)~Exclusion Criteria:~* Participation in any other clinical investigations during this investigation~* Known hypersensitivity towards any of the test products~* Symptoms of urinary tract infection (UTI) (Investigators judgement)~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intermittent catheter; SpeediCath® Standard male or female (Type: ACTIVE_COMPARATOR): Participants underwent catheterization with standard of care intermittent catheter. The catheterization was performed by a trained nurse.
- New intermittent catheter Variant 1 for male or female (Type: EXPERIMENTAL): Participants underwent catheterization with the new intermittent catheter Variant 1 for males or females. The catheterization was performed by a trained nurse.
- New intermittent catheter Variant 2 for male or female (Type: EXPERIMENTAL): Participants underwent catheterization with the new intermittent catheter Variant 2 for males or females. The catheterization was performed by a trained nurse.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Healthy volunteers may be male or female between 18 and 65 years old with a BMI of 18-32kg/m2. They must be in good health not have any health condition which could interfere with the absorption, distribution or elimination of study drug, or with the clinical and laboratory assessments in this study.~Patients enrolling in Part II of the study, may be male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2. Patients must have HBeAg positive, chronic hepatitis B with no history of clinical decompensation, and must not have been treated for hepatitis B before.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- NVR 3-778 (Type: EXPERIMENTAL): NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
- Placebo for NVR 3-778 (Type: PLACEBO_COMPARATOR): Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
- NVR 3-778 and Pegasys (Type: EXPERIMENTAL): NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
- Pegasys (Type: ACTIVE_COMPARATOR): Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Developing and Evaluating Product Messaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Consumes red meat at least once per week.~* Responsible for at least 50% of grocery shopping for the household.~* Lives in the United States~Exclusion Criteria:~* Individuals who have participated in research studies from previous aims of this research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: OTHER): Products that contain red meat will not have warning labels or an increase in price.
- Warning Labels (Type: EXPERIMENTAL): The warning labels are black octagons with white text that appear next to images of products that contain red meat. One label says WARNING: Eating red meat contributes to colon and rectal cancer and the other label says WARNING: Eating red meat harms the environment.
- Tax (Type: EXPERIMENTAL): The tax is a 30% increase in the price of products that contain red meat.
- Combined Warning Labels and Tax (Type: EXPERIMENTAL): The Combined Warning Labels and Tax arm features both the warning labels and tax. The warning labels are black octagons with white text that appear next to images of products that contain red meat. One label says WARNING: Eating red meat contributes to colon and rectal cancer and the other label says WARNING: Eating red meat harms the environment. The tax is a 30% increase in the price of red meat products.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject, of any race, who is at least 1 year of age.~* Subjects must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit mucopurulent or purulent conjunctival discharge (crusty or sticky eyelids, globular and yellow discharge) and redness in at least one eye.~* The symptoms of bacterial conjunctivitis must be present for 3 days (approximately 72 hours) or less.~* Must be willing to discontinue contact lens wear for the duration of the study.~Exclusion Criteria:~* Any uncontrolled, systemic, debilitating disease.~* Use of topical ophthalmic solutions including tear substitutes within 2 hours before and during the study.~* Use of any topical ophthalmic anti-inflammatory agents within 48 hours before and during the study.~* Any active upper respiratory tract infection.~* Pregnant or nursing females.~* Use of any antibiotic (topical or systemic) within 72 hours of enrollment

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AzaSite (Type: EXPERIMENTAL): None
- Vehicle (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete